Feedback

Browsing by N

Use an asterisk (*) for partial word searches (e.g. pemph*)

60 results found.

1.
2.
3.
Ordering Recommendation:   Confirm diagnosis of anti-NMDAR encephalitis.
4.
Ordering Recommendation:   Confirm diagnosis of NMDAR antibody encephalitis.
5.
Ordering Recommendation:   Aid in evaluation of patient with allergic signs and symptoms, such as anaphylaxis. May assist when diagnosing and monitoring mast-cell activation disorders or when evaluating histamine production over a longer time frame.
6.
7.
8.
9.
10.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
11.
Ordering Recommendation:   May help rule out narcolepsy when clinical history and sleep studies are inconclusive.
12.
Ordering Recommendation:   Aids in management of individuals receiving natalizumab therapy.
13.
14.
15.
16.
Ordering Recommendation:   Preferred test for detecting Neisseria gonorrhoeae in variety of specimens. This test does not include confirmation of positive results by an alternative nucleic acid target. If confirmation of positive results by an alternative nucleic acid target is required, refer to Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA) with Confirmation (2011164).
17.
Ordering Recommendation:   Use to assess immunocompetence following Neisseria meningitidis vaccination. To assess suspected immunodeficiency, use pre- and postvaccination serology. Do not use for diagnosis of infection or serotyping.
18.
19.
20.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
21.
Ordering Recommendation:   Acceptable test to confirm a suspected diagnosis of neurofibromatosis type 1 (NF1) in individuals not meeting NIH clinical criteria.
22.
Ordering Recommendation:   Preferred test to confirm a suspected diagnosis of neurofibromatosis type 1 (NF1) in individuals not meeting NIH clinical criteria.
23.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
24.
25.
26.
27.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
28.
29.
30.
Ordering Recommendation:   Aids in discriminating between a paraneoplastic neurologic syndromes and other encephalitis of unknown origin.
31.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
32.
Ordering Recommendation:   Functional assay helpful in screening for  CGD.
33.
34.
35.
Ordering Recommendation:   Serum nickel may be informative in the investigation of toxic exposure. Urine (0025045) is the preferred specimen for the determination of exposure. Measurement of nickel is not recommended in asymptomatic individuals or individuals with a low likelihood of exposure.
36.
Ordering Recommendation:   Urine is the preferred specimen for the determination of exposure. Measurement of nickel is not recommended in asymptomatic individuals or individuals with a low likelihood of exposure.
37.
Ordering Recommendation:   Use to detect and monitor nicotine, cotinine, and trans-3'-hydroxycotinine in serum or plasma. Serum or plasma testing may be useful when a valid urine specimen cannot be obtained (anuretic or dialysis).
38.
Ordering Recommendation:   Recommended for determination of active, passive, and differentiation between nicotine replacement and tobacco use. For a screening test to determine active exposure to nicotine and compliance with smoking-cessation programs, Cotinine Screen Urine (2007081) is preferred.
39.
Ordering Recommendation:   Diagnostic testing for Niemann-Pick disease, type A.  Carrier screening for Niemann-Pick disease, type A.
40.
Ordering Recommendation:   Diagnostic testing for Niemann-Pick disease, type A.
41.
42.
Ordering Recommendation:   Use as an aid in the diagnosis of urothelial carcinoma in conjunction with standard diagnostic procedures and monitoring tumor recurrence.
43.
Ordering Recommendation:   Detect Nocardia and other aerobic actinomycetes.
44.
Ordering Recommendation:   Not a recommended test. Test has limited clinical value in assessing risk for pregnancy-related morbidity and thrombosis in antiphospholipid syndrome (APS).
45.
Ordering Recommendation:   Acceptable panel for second-line testing for antiphospholipid syndrome (APS) risk estimation when results for aPL criteria tests are negative or equivocal.
46.
Ordering Recommendation:   For gestational age of 9 weeks or older.
Screening test utilizing placental cell-free DNA (cfDNA) in maternal blood.
Screens for whole chromosome aneuploidy involving chromosomes 13, 18, 21, X, Y, and triploidy.
Recommended for women at high risk for fetal chromosomal aneuploidy.
47.
Ordering Recommendation:   For gestational age of 9 weeks or older.
Screening test utilizing placental cell-free DNA (cfDNA) in maternal blood.
Screens for whole chromosome aneuploidy involving chromosomes 13, 18, 21, X, Y, and triploidy.
Also screens for microdeletions causing 22q11.2 deletion; 1p36 deletion; Angelman, Prader-Willi, and cri-du-chat syndromes.
Recommended for women at high risk for fetal chromosomal aneuploidy who also wish to screen for the listed microdeletions.
48.
Ordering Recommendation:   For gestational age of 9 weeks or older.
Screening test utilizing placental cell-free DNA (cfDNA) in maternal blood.
Screens for whole chromosome aneuploidy involving chromosomes 13, 18, 21, X, Y, and triploidy.
Also screens for microdeletions causing 22q11.2 deletion syndrome (DiGeorge/velocardiofacial syndrome).
Recommended for women at high risk for fetal chromosomal aneuploidy.
49.
Ordering Recommendation:   Assess risk for alloimmune hemolytic disease of the newborn by analyzing fetal circulating cell-free DNA in maternal blood.
This test provides a fetal RhD genotype and gender using a maternal whole blood specimen.
Mother must be pregnant and greater than 10 weeks gestation at time of draw. Refer to Specimen Required section below for more specifics.
50.
Ordering Recommendation:   Only intended for use in patients with non-alcoholic liver disease (NAFLD); results may be inaccurate in patients with other etiologies of liver disease.
51.
Ordering Recommendation:   Preferred test for individuals with clinical phenotype of Noonan syndrome, cardiofaciocutaneous syndrome, Costello syndrome, LEOPARD syndrome, Legius syndrome, or Noonan-like syndrome.
52.
Ordering Recommendation:   Prenatal testing for fetus with ultrasound findings suggestive of Noonan syndrome, such as cystic hygroma, increased nuchal translucency, or polyhydramnios.
53.
Ordering Recommendation:   Acceptable initial test to confirm a clinical diagnosis of Noonan syndrome or LEOPARD syndrome.
54.
Ordering Recommendation:   Acceptable initial test to confirm a clinical diagnosis of Noonan syndrome or LEOPARD syndrome.
55.
Ordering Recommendation:   Acceptable secondary test if no pathogenic mutations are detected with PTPN11 testing.
56.
57.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
58.
Ordering Recommendation:   Initial test for prognostication of CN-AML.
59.
Ordering Recommendation:   Predicts response to anti-EGFR and MAPK pathway therapies in a variety of malignancies (eg, melanoma and colorectal cancer).
60.
Ordering Recommendation:   Use Nuclear Antibody (ANA) by IFA, IgG as a follow up to a positive ANA screening test.